参考文献/References:
[1] de Camargo B,de Oliveira Santos M,Rebelo MS,et al.Cancer inci-dence among children and adolescents in Brazil:first report of 14 population-based cancer registries.Int J Cancer,2010,126(3):715-720.
[2] Li J,Thompson TD,Miller JW,et al.Cancer incidence among chil-dren and adolescents in the United States,2001-2003.Pediatrics,2008,121(6):el470-1477.
[3] 鲍萍萍,郑莹,王春芳,等.2002~2004年上海市儿童恶性肿瘤发病特征.中国肿瘤,2009,18(2):119-122.
[4] Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010.CA Cancer J Clin,2010,60(5):277-300.
[5] Higashi T,Kudo T,Kinuya S.Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan:current issues with histori-cal review and future perspective.Ann Nucl Med,2012,26(2):99-112.
[6] Chawla SC,Federman N,Zhang D,et al.Estimated cumulative radiation dose from PET/CT in children with malignancies:a 5-year retrospective review.Pediatr Radiol,2010,40(5):681-686.
[7] Alessio AM,Kinahan PE,Manchanda V,et al.Weight-based,low-dose pediatric whole-body PET/CT protocols.J Nucl Med,2009,50(10):1570-1577.
[8] Fahey FH,Dosimetry of Pediatric PET/CT.J Nucl Med,2009,50(9):1483-1491.
[9] Gelfand MJ,Lemen LC.PET/CT and SPECT/CT dosimetry in children:the challenge to the pediatric imager.Semin Nucl Med,2007,37(5):391-398.
[10] Hahn K,Pfluger T.Is PET/CT necessary in paediatric oncology? Against.Eur J Nucl Med Mol Imaging,2006,33(8):966-968.
[11] Riad R,Omar W,Kotb M,et al.Role of PET/CT in malignant pedi-atric lymphoma.Eur J Nucl Med Mol Imaging,2010,37(2):319-329.
[12] Olson MR,Donaldson SS.Treatment of pediatric hodgkin lym-phoma.Curr Treat Options Oncol,2008,9(1):81-94.
[13] Freed J,Kelly KM.Current approaches to the management of pediatric Hodgkin lymphoma.Paediatr Drugs,2010,12(2):85-98.
[14] Miller E,Metser U,Avrahami G,et al.Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients.J Comput Assist Tomogr,2006,30(4):689-694.
[15] Punwani S,Taylor SA,Bainbridge A,et al.Pediatric and adolescent lymphoma:comparison of whole-body STIR half-FourierRARE MR imaging with an enhanced PET/CT reference for initial staging.Radiology,2010,255(1):182-190.
[16] Sharma P,Gupta A,Patel C,et al.Pediatric lymphoma:metabolic tumor burden as a quantitative index for treatment response evalu-ation.Ann Nucl Med,2012,26(1):58-66.
[17] Mardis N,Wong CY.The accuracy of PET(CT) in evaluating pedi-atric lymphoma.J Pediatr Hematol Oncol,2007,29(9):667-668.
[18] Levine JM,Weiner M,Kelly KM.Routine use of PET scans after completion of therapy in pediatric Hodgkin diseaseresults in a high false positive rate.J Pediatr Hematol Oncol,2006,28(11):711-714,
[19] Riad R,Omar W,Sidhom I,et al.False-positive F-18 FDG uptake in PET/CT studies in pediatric patients withabdominal Burkitt’s lym-phoma.Nucl Med Commun,2010,31(3):232-238.
[20] Mody RJ,Bui C,Hutchinson RJ,et al.Comparison of 18F Flurodeoxyglucose PET with Ga-67 scintigraphy andconventional imaging modalities in pediatric lymphoma.Leuk Lymphoma,2007,48(4):699-707.
[21] Hines-Thomas M,Kaste SC,Hudson MM,et al.Comparison of gal-lium and PET scans at diagnosis and follow-up of pediatricpatients with Hodgkin lymphoma.Pediatr Blood Cancer,2008,51(2):198-203.
[22] Morris EB,Gajjar A,Okuma JO,et al.Survival and late mortality in long-term survivors of pediatric CNS tumors.J Clin Oncol,2007,25(12):1532-1538.
[23] Arora B,Parikh PM.PET-CT scan in pediatric oncology:where,when,how and at what price.Indian J Cancer,2010,47(4):355-359.
[24] Pirotte BJ,Lubansu A,Massager N,et al.Clinical interest of inte-grating positron emission tomography imaging in theworkup of 55 children with incidentally diagnosed brain lesions.J Neurosurg Pediatr,2010,5(5):479-485.
[25] Pirotte BJ,Lubansu A,Massager N,et al.Clinical impact of inte-grating positron emission tomography during surgery in 85 children with brain tumors.J Neurosurg Pediatr,2010,5(5):486-499.
[26] Pirotte B,Levivier M,Morelli D,et al.Positron emission tomogra-phy for the early postsurgical evaluation of pediatricbrain tumors.Childs Nerv Syst,2005,21(4):294-300.
[27] Kruer MC,Kaplan AM,Etzl MM Jr,et al.The value of positron emission tomography and proliferation index in predictingprogres-sion in low-grade astrocytomas of childhood.J Neurooncol,2009,95(2):239-245.
[28] Zukotynski KA,Fahey FH,Kocak M,et al.Evaluation of 18F-FDGPET and MRI associations in pediatric diffuse intrinsicbrain stem glioma:a report from the Pediatric Brain Tumor Consortium.J Nucl Med,2011,52(2):188-195.
[29] Spence AM,Muzi M,Mankoff DA,et al.18F-FDG PET of gliomas at delayed intervals:improved distinction between tumorand normal gray matter.J Nucl Med,2004,45(10):1653-1659.
[30] Utriainen M,Metsahonkala L,Salmi TT,et al.Metabolic character-ization of childhood brain tumors:comparison of 18F-fluo-rodeoxyglucose and 11C-methionine positron emission tomography.Cancer,2002,95(6):1376-1386.
[31] Phi JH,Paeng JC,Lee HS,et al.Evaluation of focal cortical dyspla-sia and mixed neuronal and glial tumors inpediatric epilepsy pa-tients using 18F-FDG and 11C-methionine pet.J Nucl Med,2010,51(5):728-734.
[32] Chen W,Silverman DH,Delaloye S,et al.18F-FDOPA PET imaging of brain tumors:comparison study with 18F-FDG PET andevalua-tion of diagnostic accuracy.J Nucl Med,2006,47(6):904-911.
[33] Walter F,Federman N,Apichairuk W,et al.18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatricpatients.Pedi-atr Hematol Oncol,2011,28(7):579-587.
[34] Bestic JM,Peterson JJ,Bancroft LW.Pediatric FDG PET/CT:Physiologic uptake,normal variants,and benign conditions[cor-rected].Radiographics,2009,29(5):1487-1500.
[35] Ricard F,Cimarelli S,Deshayes E,et al.Additional Benefit of F-18 FDG PET/CT in the staging and follow-up of pediatricrhab-domyosarcoma.Clin Nucl Med,2011,36(8):672-677.
[36] Tateishi U,Yamaguchi U,Seki K,et al.Bone and soft-tissue sarco-ma:preoperative staging with fluorine 18fluorodeoxyglucose PET/CT and conventional imaging.Radiology,2007,245(3):839-847.
[37] Walter F,Czemin J,Hall T,et al.Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarco-ma patients?.J Pediatr Hematol Oncol,2012,34(2):131-136.
[38] Bentzen L,Keiding S,Nordsmark M,et al.Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographicneedle electrodes in human soft tissue tumours.Radiother Oncol,2003,67(3):339-344.
[39] Tateishi U,Yamaguchi U,Maeda T,et aL Staging performance of carbon-11 choline positron emission tomography/computed tomog-raphy in patients with bone and soft tissue sarcoma:comparison withconventional imaging.CancerSci,2006,97(10):1125-1128.
[40] Lpci E,Piccardo A,Nanni C,et al.18F-DOPA PET/CT in neurob-lastoma:comparison of conventional imaging with CT/MR.Clin Nucl Med,2012,37(4):e73-78.
[41] Levine DS,Metzger DL,Nadel HR,et al.Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocy-tomasyndrome.Pediatr Radiol,2011,41(10):1321-1325.
[42] Radhakrishnan V,Kumar R,Malhotra A,et al.Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma:a prospective study.J Nucl Med,2012,53(2):191-198.
[43] Bertagna F,Orlando E,Bosio G,et al.Incremental diagnostic value of F-18 FDG PET/CT over MRI in a pediatric patientwith suspected hepatoblastoma and histologic diagnosis of focal nodularhyperpla-sia.Clin Nucl Med,2011,36(4):305-308.
[44] Kumar J,Seith A,Kumar A,et al.Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pedi-atric patients with small-cell neoplasms:comparison withskeletal scintigraphy and FDG PET/CT.Pediatr Radiol,2008,38(9):953-962.
[45] Piwkowski P,Kolodziejczyk A,Macioszek A,et al.Potential role of PET-CT in chemotherapy efficacy assessment and recurrencediag-nosis in a patient with a Wilms’ tumour.Nucl Med Rev Cent East Eur,2011,14(1):33-35.
[46] Mackie GC,Shulkin BL,Ribeiro RC,et al.Use of 18F-fluo-rodeoxyglucose positron emission tomography in evaluating local-lyrecurrent and metastatic adrenocortical carcinoma.J Clin Endocrinol Metab,2006,91(7):2665-2671.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[10]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]